tuftsin has been researched along with fluconazole in 1 studies
| Studies (tuftsin) | Trials (tuftsin) | Recent Studies (post-2010) (tuftsin) | Studies (fluconazole) | Trials (fluconazole) | Recent Studies (post-2010) (fluconazole) |
|---|---|---|---|---|---|
| 534 | 4 | 58 | 9,343 | 721 | 3,664 |
| Protein | Taxonomy | tuftsin (IC50) | fluconazole (IC50) |
|---|---|---|---|
| Lanosterol 14-alpha demethylase | Candida albicans SC5314 | 0.1296 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 9.21 | |
| Sterol 14-alpha demethylase | Trypanosoma cruzi strain CL Brener | 0.88 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khan, A; Khan, MA; Owais, M | 1 |
1 other study(ies) available for tuftsin and fluconazole
| Article | Year |
|---|---|
Prophylactic use of liposomized tuftsin enhances the susceptibility of Candida albicans to fluconazole in leukopenic mice.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Colony Count, Microbial; Drug Resistance, Fungal; Fluconazole; Immunologic Factors; Kidney; Leukopenia; Liposomes; Macrophages; Mice; Mice, Inbred BALB C; Phagocytosis; Tuftsin | 2006 |